No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
PEPG PepGen
- 11.700
- -0.130-1.10%
Close Apr 25 16:00 ET
- 11.700
- 0.0000.00%
Post 16:02 ET
378.55MMarket Cap-3545P/E (TTM)
11.920High10.850Low34.79KVolume11.610Open11.830Pre Close398.09KTurnover0.22%Turnover RatioLossP/E (Static)32.35MShares17.51052wk High3.49P/B185.81MFloat Cap3.72052wk Low--Dividend TTM15.88MShs Float20.000Historical High--Div YieldTTM9.05%Amplitude3.720Historical Low11.442Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Edgewise Gets EU Orphan Drug Status for Muscular Dystrophy Drug
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersPaxMedica (NASDAQ:PXMD) stock moved upwards by 104.2% to $0.84 during Friday's pre-market session. The market value of their outstanding shares is at $6.2 million. Allarity Therapeutics (NASDAQ
Insiders Buying GameStop And 2 Other Stocks
Although U.S. stocks closed mixed on Tuesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the sto
PepGen to Participate in Upcoming Investor Conferences
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of
Express News | PepGen Receives U.S. FDA Orphan Drug And Rare Pediatric Disease Designations For PGN-EDO51 For The Treatment Of Duchenne Muscular Dystrophy
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
PepGen Inc. (Nasdaq: PEPG) today announced that the U.S. Food and Drug Administration (FDA) granted both orphan drug and rare pediatric disease designations for PGN-EDO51, an investigational therapeutic for Duchenne muscular dystrophy (DMD) patients whose mutations are amenable to an exon 51 skipping approach. PepGen is evaluating PGN-EDO51 for the treatment of DMD in the ongoing CONNECT1 Phase 2 trial, and expects to begin enrolling patients in the CONNECT2 Phase 2 trial later this year.
Comments
$PepGen(PEPG.US$ PepGen Receives U.S. FDA Orphan Drug And Rare Pediatric Disease Designations For PGN-EDO51 For The Treatment Of Duchenne Muscular Dystrophy
4
Mary Beth DeLena's addition to PepGen's executive team is viewed positively, her vast legal and compliance experience is anticipated to significantly contribute to PepGen's aim of providing next-gen oligonucleotide therapies for severe neuromuscular and neurological diseases.
PepGen Inc. dosed their first patient for the treatment of Duchenne muscular dystrophy (DMD)
$PepGen(PEPG.US$
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the first patient has been dosed in its CONNECT1-EDO51 Phase 2, open-label multiple ascending dose (MAD) clinical trial evaluating PGN-EDO51 for the ...
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the first patient has been dosed in its CONNECT1-EDO51 Phase 2, open-label multiple ascending dose (MAD) clinical trial evaluating PGN-EDO51 for the ...
1
Will be watching for data to come
$PepGen(PEPG.US$ PepGen Announced First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping
Benzinga· 5 mins ago
Benzinga· 5 mins ago
1
Update! Watching!
$PepGen(PEPG.US$ promising data from their 5mg/Kg dose level cohort, which is expected to be shared in mid-2024. This data suggests a high dystrophin expression, which is a strong indicator of PGN-EDO51’s effectiveness. In a head-to-head comparison with SRP-5051, PGN-EDO51 showed a 13-fold increase in exon skipping. Additionally, PepGen’s PGN-EDODM1 has shown promising early results, with significant correction of mis-splicing and myotonia after a single dose, and a tolerabili...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
sendhelp : any tips on the "emotion" side of trading? I tend to panic sell when it dips thinking it will keep dropping but it ends up rising right after, like in $NuCana (NCNA.US)$ I brought it avg 0.83 and sold it for 0.71 when it dip down..
TrytosaveabitOP sendhelp: First PM and AM are hard to trade because you don’t get a true picture of interest/liquidity. Second use your indicators and volume to decide if it’s a actual dip or is it drop on low volume! Here is what I recommend indicator wise! 8 and 9 EMA on the 5, 10 and 15 minute charts after i am already in a ticker! But remember volatility and volume have to be used in tandem! That way if drops below your indicator it could just be a SL, or a bit of profit taking but will recover! I seen the drop you’re talking about and it was a low volume drop that didn’t bother me! Hope this helps?
sendhelp TrytosaveabitOP: I see now, thanks a lot! Are you still positive with the ticker $NuCana (NCNA.US)$ ? and do you think I could possibly reenter maybe during market open?
TrytosaveabitOP sendhelp: I am still positive on it! I am actually looking to try to get back in below .80 to see what happens at 8:00 and then into market open! NFA JMO! GL